Cara Therapeutics reported $10.81M in Sales Revenues for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Acadia Pharmaceuticals ACAD:US USD 130.71M 3.85M
Acelrx Pharmaceuticals ACRX:US USD 507K 63K
Cara Therapeutics CARA:US USD 10.81M 12.19M
Chugai Pharma 4519:JP JPY 225.28B 10.33B
Depomed DEPO:US USD 34.21M 919K
Endo International Ordinary Shares ENDP:US USD 541.69M 27.42M
Halozyme Therapeutics HALO:US USD 208.98M 56.61M
Horizon Pharma HZNP:US USD 925.36M 48.95M
Johnson & Johnson JNJ:US USD 23.71B 85M
Neurocrine Biosciences NBIX:US USD 387.9M 9.7M
Pacira Pharmaceuticals PCRX:US USD 167.47M 1.94M
Pfizer PFE:US USD 22.64B 5.1B
Revance Therapeutics RVNC:US USD 29.01M 647K
Supernus Pharmaceuticals SUPN:US USD 177.35M 7.3M
Teva Pharmaceutical Industries TEVA:US USD 3.6B 191M
Vanda Pharmaceuticals VNDA:US USD 130.64M 1.86M